Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Changhoon Yoo
Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer: longer-term follow-up from the randomised, double-blind, placebo-controlled, phase 3 KEYNOTE-966 trial
Keywords Biliary tract cancer Chemotherapy Long-term follow-up Pembrolizumab Evidence before this study We searched PubMed and Google Scholar on Jan 26, 2026 for randomised controlled trials published in English since the database inception using the terms “PD-1 inhibitor” OR “PD-L1 inhibitor” OR “immune checkpoint inhibitor” AND “unresectable” OR “metastatic” AND “biliary tract cancer” OR “BTC” OR “cholangiocarcinoma” OR “gallbladder cancer”.
Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial
Abstract Biliary tract cancers (BTCs) are associated with poor outcomes despite recent incorporation of immune checkpoint inhibitors into first-line chemotherapy. Human epidermal growth factor receptor 2 (HER2) overexpression or amplification defines a therapeutically targetable subset of BTC but its integration into first-line chemoimmunotherapy has not been prospectively evaluated.
Systemic Therapy for Advanced Biliary Tract Cancers in 2026: Current Standard of Care and Emerging Therapeutic Strategies
1 Introduction Biliary tract cancer (BTC) is a heterogeneous group of epithelial malignancies arising from the biliary tree, which include intrahepatic cholangiocarcinoma (iCCA), extrahepatic cholangiocarcinoma (eCCA), and gallbladder cancer (GBC). Distinct site-specific biology and genomic alterations underlie heterogeneity in clinical course across these subtypes [1].
Liposomal irinotecan for previously treated patients with biliary tract cancer: A pooled analysis of NIFTY and NALIRICC trials
BACKGROUND & AIMS: Liposomal irinotecan (nal-IRI) combined with fluorouracil (5-FU)/leucovorin (LV) as a second-line treatment for biliary tract cancer (BTC) following progression on gemcitabine-based therapy yielded conflicting outcomes in the Korean NIFTY and German NALIRICC trials. This necessitated a comprehensive pooled analysis to evaluate its efficacy and safety. METHODS: Individual patient data were pooled from the intention-to-treat populations of the NIFTY and NALIRICC trials.
Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors | Future Oncology
Inactivation of the tumor suppressor protein p53 is an important mechanism by which tumors promote their survival and proliferation [1]. Inactivation of p53 may occur due to a mutation of the TP53 gene, which encodes p53, or amplification of mouse double minute 2 homolog (MDM2), which encodes MDM2, an endogenous negative regulator of p53 [1].
Reply: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial - author's reply - PubMed
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
A randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours | British Journal of Cancer
Abstract Background Imatinib re-challenge is one of the available therapeutic options for patients with treatment-refractory gastrointestinal stromal tumours (GIST). Intermittent dosing of imatinib was suggested to delay outgrow of the imatinib-resistant clones in a preclinical study, and it could potentially reduce the adverse events.
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
Background Biliary tract cancers, which arise from the intrahepatic or extrahepatic bile ducts and the gallbladder, generally have a poor prognosis and are rising in incidence worldwide. The standard-of-care treatment for advanced biliary tract cancer is chemotherapy with gemcitabine and cisplatin. Because most biliary tract cancers have an immune-suppressed microenvironment, immune checkpoint inhibitor monotherapy is associated with a low objective response rate.
Second-line liposomal irinotecan plus fluorouracil and leucovorin in metastatic biliary tract cancer - Author's reply
1 Yoo C Kim K-p Jeong JH et al. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. Lancet Oncol. 2021; 22: 1560-1572 Molecular biomarker analysis was not mandatory for the NIFTY trial because no approved targeted therapy for the management of biliary tract cancer existed when the trial was designed and initiated.
Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study
Summary Background The prognosis of patients with advanced biliary tract cancer who have progressed on gemcitabine plus cisplatin is dismal. We aimed to investigate the efficacy and safety of second-line liposomal irinotecan plus fluorouracil and leucovorin in patients with metastatic biliary tract cancer that has progressed on gemcitabine plus cisplatin.
Corrigendum to ‘Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer’, [Eur J Canc 51 (2015) 482-488] - European Journal of Cancer
Min-Hee Ryu 1 Author Footnotes 1 contributed equally and should be considered co-first authors. Min-Hee Ryu Footnotes 1 contributed equally and should be considered co-first authors. Affiliations Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea Search for articles by this author Changhoon Yoo 1 Author Footnotes 1 contributed equally and should be considered co-first authors.
Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib
Advertisement Advertisement Jae‐Joon Kima,†, Min‐Hee Ryua,†, Changhoon Yooa, Mo Youl Becka, Jung Eun Maa and Yoon‐Koo Kang (ykkang{at}amc.seoul.kr)*,a a Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea ↵*Correspondence: Yoon‐Koo Kang, M.D., Ph.D., Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic‐ro 43‐gil, Songpa‐gu, Seoul, 05505, Korea.
Association between the exposure to anti-angiogenic agents and tumour immune microenvironment in advanced gastrointestinal stromal tumours
Abstract Background Tumour immune microenvironment (TIME) of gastrointestinal stromal tumours (GISTs) is largely unknown. Methods A total of 81 surgical specimens from 67 patients with advanced GISTs were categorised into treatment groups: tyrosine kinase inhibitor (TKI)-naive, n = 20; imatinib-progressed and no exposure to sunitinib or regorafenib (IM-PD), n = 30; and imatinib-progressed and sunitinib and/or regorafenib-treated (IM-PD/SU-treated), n = 31.
Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Fig. 1 Genetic landscape of biliary tract cancer. The oncoprint displays the most frequent and most clinically meaningful genetic mutations according to the primary site of malignancy, the aetiology, the disease extent at the time of diagnosis and the surgical history.
Long‐term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14‐year, single‐center experience - Kim - - Cancer Medicine - Wiley Online Library
ORIGINAL RESEARCH Long‐term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14‐year, single‐center experience Yoon‐Koo Kang Corresponding Author E-mail address: ykkang@amc.seoul.kr Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Correspondence Yoon‐Koo Kang, Department of Oncology, Asan Medical Center, University of Ulsan College of...
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Changhoon
Contact Changhoon, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack